OBJECTIVE:To probe into the application value of clozapine combined with aripiprazole in the treatment of metabolic syndrome（MS） in patients with schizophrenia.METHODS:Totally 120 patients with schizophrenia admitted into Mental Health Center Affiliated to Huazhong University of Science and Technology from Jul.1 st

2017 to Jun.30 th

2018 were extracted as the research objects.And retrospective analysis was performed.Patients were divided into the clozapine group（treated with clozapine）

the aripiprazole group（treated with aripiprazole）

and the combined treatment group（treated with clozapine combined with aripiprazole） according to different treatment regimens

with 40 cases in each group.Before treatment and after treatment of 4

8 and 16 weeks

changes in levels of metabolism-related indicators of three groups were observed

and the positive and negative syndrome scale（PANSS） and the treatment emergent symptom scale（TESS） were evaluated compare the effects of three treatment regimens on the occurrence of MS in patients.RESULTS:After 4 weeks of treatment

the PANSS score and negative symptom score of the combined treatment group were significantly lower than those of the clozapine group（P

<

0.05）;after 8 and 16 weeks of treatment

the PANSS score

negative symptom score and positive symptom score of patients in the combined treatment group were significantly lower compared with the clozapine group

the difference was statistically significant（P

<

0.05）;after 4 weeks of treatment

there was no significant difference in PANSS score

negative symptom score and positive symptom score between the combined treatment group and the aripiprazole group（P

>

0.05）;After 8 weeks and 16 weeks of treatment

the PANSS score

positive symptom score and negative symptom score of the combined treatment group were significantly lower than those of the aripiprazole group

and the differences were statistically significant（P

<

0.05）.After 16 weeks of treatment

the levels of fasting blood glucose

blood lipid

body mass index and other metabolism-related indicators in the combined treatment group and aripiprazole group were significantly lower than those in the clozapine group

the differences were statistically significant（P

<

0.05）

while there was no significant difference between the combined treatment group and the aripiprazole group（P

>

0.05）.After treatment

the incidence of MS in the combined treatment group

clozapine group and aripiprazole group were 7.5%（3/40）

32.5%（13/40） and 5%（2/40）

respectively;the incidence of MS in the combined treatment group was significantly lower than that in the clozapine group

the difference was statistically significant（χ

2

=7.813

P=0.005）

yet there was no significant difference compared with the aripiprazole group（χ

2

=0.213

P=0.644）.In terms of adverse drug reactions

there was no significant difference in TESS scores of three groups after treatment of 4

8 and 16 weeks（P

>

0.05）.CONCLUSIONS:The combined treatment of clozapine and aripiprazole is more effective than monotherapy of clozapine and aripiprazole

and the incidence of MS is lower than that of clozapine alone.